Acacia Pharma raises $23.

Dr Alex Pasteur of Fidelity Biosciences and Dr Martin Edwards of Novo A/S have joined the Table of Acacia Pharma as Non-executive Directors. Acacia Pharma use the proceeds to: complete Phase III advancement of APD421 for preventing post-operative nausea & vomiting ; complete Phase II development of APD403 for preventing chemotherapy induced nausea & vomiting ; and develop the commercial display of APD515 for the treatment of xerostomia in advanced cancer patients. Related StoriesSurgical startup seeks financing to build digital reality training libraryDiabetic retinopathy therapy improvements: an interview with Richard Kirk, CEO of PolyphotonixGenetic carrier screening: an interview with Don Hardison, CEO of Good Start Genetics I am delighted to welcome Fidelity and Novo to the business and want to thank Gilde and Lundbeckfond for their continuing support, commented Dr Julian Gilbert, Acacia Pharma's CEO.The other studies investigated patients with STEMI/ACS. Sanofi-Aventis provided all data requested by IQWiG for the 3 largest and most important research. In this way, important data inaccessible to the public could be incorporated into the assessment previously. Related StoriesLowering blood pressure below suggested targets reduces risk of stroke currently, heart attackResearch shows winter can increase risk of severe form of heart attackGood sleep patterns are best for your heartPatients with severe coronary syndrome without ST-segment elevation: clopidogrel plus ASA does not have any effect on mortality The results of the only study that could be assessed in sufferers with ACS without ST-segment elevation provided evidence that patients using mixture therapy experienced fewer center attacks.